Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indatuximab ravtansine - Biotest AG

X
Drug Profile

Indatuximab ravtansine - Biotest AG

Alternative Names: Anti-myeloma monoclonal antibody-DM4 immunoconjugate BT-062; BT-062; Maytansinoid-conjugated anti-myeloma monoclonal antibody BT-062; N2'-Deacetyl-N2'-[4-Methyl-4-(Oxobuthyldithio)-1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal Antibody; nBT062

Latest Information Update: 27 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotest
  • Developer Biotest AG
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Multiple myeloma

Most Recent Events

  • 25 Apr 2022 Biotest AG has been acquired by Grifols
  • 31 Dec 2020 Biotest terminates its license agreement with Immunogen for maytansinoid ADC technology
  • 04 Feb 2020 No development reported - Phase-II for Bladder cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium, Germany (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top